A case of prostatic adenocarcinoma recurrence presenting as ductal carcinoma of the prostate

Metastatic ductal carcinoma of the prostate: a rare variant responding to a common treatment

Ductal carcinoma of the prostate is a rare histologic subtype of prostate carcinoma. It represents 0.4% to 0.8% of all prostate cancers and is associated with a poor prognosis. Given the paucity of cases reported in the literature on ductal prostate carcinoma, little is known about how this cancer responds to cytotoxic chemotherapy. We report the case of a 56-year-old male who presented to our clinic with hemoptysis, cough and hematuria and was found to have metastatic ductal carcinoma of the prostate. He was initiated on docetaxel chemotherapy, which has been previously shown to improve overall survival in patients with metastatic prostate adenocarcinoma, but has never been studied in this less common subtype of prostate cancer. To the best of our knowledge, the following is the first reported case of a patient with metastatic ductal carcinoma of the prostate responding to docetaxel chemotherapy.

[Ductal Adenocarcinoma of the prostate with infiltration of the bladder. Can radical cystectomy and antiandrogen therapy cure the disease?]

Ductal adenocarcinoma of the prostate is a rare entity. The lack of correlation between the prostate-specific antigen value and the tumor stage, as well as early dissemination, are major differences from acinar cancer. Due to a lack of early symptoms, the tumor is often found in an advanced stage. Urinary obstruction and hematuria lead to clinical assessment. The characteristic tumor growth near the seminal colliculus can yield a negative digital rectal examination. Despite a lack of treatment guidelines, authors recommend an aggressive surgical concept. First approaches include radical prostatectomy, transurethral resection, and high-dose radiotherapy. Subsequent androgen deprivation is recommended. We report the case of a 64-year-old man with ductal prostate cancer who underwent radical cystectomy followed by androgen deprivation therapy. This is the first such case reported in both the German and the English literature.